Groupama Asset Managment Sells 7,743 Shares of Intuitive Surgical, Inc. $ISRG

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Groupama Asset Managment trimmed its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 11.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,963 shares of the medical equipment provider's stock after selling 7,743 shares during the quarter. Groupama Asset Managment's holdings in Intuitive Surgical were worth $29,000,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Castleark Management LLC boosted its position in shares of Intuitive Surgical by 3.4% in the fourth quarter. Castleark Management LLC now owns 90,469 shares of the medical equipment provider's stock valued at $47,221,000 after acquiring an additional 2,990 shares during the period. Arlington Trust Co LLC boosted its position in shares of Intuitive Surgical by 34.5% in the first quarter. Arlington Trust Co LLC now owns 745 shares of the medical equipment provider's stock valued at $369,000 after acquiring an additional 191 shares during the period. Aveo Capital Partners LLC boosted its position in shares of Intuitive Surgical by 37.4% in the first quarter. Aveo Capital Partners LLC now owns 727 shares of the medical equipment provider's stock valued at $390,000 after acquiring an additional 198 shares during the period. Aaron Wealth Advisors LLC boosted its position in shares of Intuitive Surgical by 3.2% in the first quarter. Aaron Wealth Advisors LLC now owns 2,509 shares of the medical equipment provider's stock valued at $1,243,000 after acquiring an additional 78 shares during the period. Finally, Longbow Finance SA boosted its position in shares of Intuitive Surgical by 132.0% in the first quarter. Longbow Finance SA now owns 19,699 shares of the medical equipment provider's stock valued at $9,756,000 after acquiring an additional 11,209 shares during the period. Institutional investors own 83.64% of the company's stock.

Analyst Upgrades and Downgrades

ISRG has been the subject of a number of recent research reports. UBS Group boosted their target price on shares of Intuitive Surgical from $547.00 to $585.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $615.00 price objective on shares of Intuitive Surgical in a research report on Tuesday. BTIG Research upped their price objective on shares of Intuitive Surgical from $566.00 to $571.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft cut shares of Intuitive Surgical from a "hold" rating to a "sell" rating and cut their price objective for the stock from $515.00 to $440.00 in a research report on Monday, June 9th. Finally, Evercore ISI upped their price objective on shares of Intuitive Surgical from $470.00 to $550.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Thirteen investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Intuitive Surgical currently has an average rating of "Moderate Buy" and a consensus target price of $595.95.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Myriam Curet sold 4,500 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the completion of the sale, the executive vice president owned 353 shares of the company's stock, valued at approximately $173,845.44. This represents a 92.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Mark Brosius sold 216 shares of the stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $563.11, for a total value of $121,631.76. Following the transaction, the senior vice president owned 907 shares in the company, valued at $510,740.77. The trade was a 19.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 15,839 shares of company stock valued at $7,896,972. 0.70% of the stock is currently owned by company insiders.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock traded up $6.28 on Friday, hitting $476.16. The stock had a trading volume of 2,023,902 shares, compared to its average volume of 1,973,062. The stock has a 50 day moving average of $504.42 and a 200 day moving average of $522.06. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $616.00. The firm has a market capitalization of $170.69 billion, a P/E ratio of 66.41, a PEG ratio of 4.92 and a beta of 1.59.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The company had revenue of $2.44 billion during the quarter, compared to the consensus estimate of $2.35 billion. During the same quarter in the prior year, the firm posted $1.78 earnings per share. The firm's revenue was up 21.4% compared to the same quarter last year. Equities analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.